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Background: There is scarce scientific information assessing participants’ perception of 
pharmaceutical research in developed and developing countries concerning the risks, safety, 
and purpose of clinical trials.
Methods: To assess the perception that 604 trial participants (cases) and 604 nonparticipants 
(controls) of pharmaceutical clinical trials have about pharmaceutical clinical research, we 
surveyed participants with one of four chronic diseases from 12 research sites throughout 
Mexico.
Results: Participation in clinical trials positively influences the perception of pharmaceutical 
clinical research. More cases (65.4%) than controls (50.7%) perceived that the main purpose of 
pharmaceutical research is to cure more diseases and to do so more effectively. In addition, more 
cases considered that there are significant benefits when participating in a research study, such 
as excellent medical care and extra free services, with this being the most important motivation 
to participate for both groups (cases 52%, controls 54.5%). We also found a sense of trust in 
their physicians to deal with adverse events, and the perception that clinical research is a benefit 
to their health, rather than a risk. More controls believed that clinical trial participants’ health 
is put at risk (57% vs 33.3%). More cases (99.2%) than controls (77.5%) would recommend 
participating in a clinical trial, and 90% of cases would enroll in a clinical trial again.
Conclusion: Participation in clinical trials positively influences the perception that participants 
have about pharmaceutical clinical research when compared to nonparticipants. This informa-
tion needs to be conveyed to clinicians, public health authorities, and general population to 
overcome misconceptions.
Keywords: perceptions, clinical trials, chronic disorders, participants’ perception, pharmaceuti-
cal industry, developing countries
Introduction
During the past 3 decades, pharmaceutical clinical trials have intensively increased 
worldwide, significantly expanding into developing countries.1–3 In the last 5 years, 
registration of research conducted in Latin America in the ClinicalTrials.gov registry 
has increased from 4,499 to 11,100.4
As a consequence of ethical misconduct by some researchers, both the international 
clinical research regulations and the concern of providing appropriate protection 
to clinical research participants have grown intensively.5,6 Unfortunately, a lack of 
audits or inspections in many clinical research sites all over the world is evident.1,3,7 
Certification by well-known associations focusing on the protection of participants is 
now highly recommended by public health agencies.8 Despite these efforts to ensure 
ethical behavior regarding participant protection in clinical research, there is still very 
limited information regarding the participants’ perception of the risks, safety, and 
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purpose of clinical trials.9–13 Recent efforts have been made 
to approach clinical research participants and assess their 
perception and experiences with tools such as the Research 
Participant Perception Survey and organizations such as 
the Patient-Centered Outcomes Research Institute.11,13–16 
Nevertheless, these efforts still focus on developed countries 
and clinical research sites with certified clinical practice 
excellence. Comparing the perceptions of participants from 
the USA and the rural and urban People’s Republic of China 
yielded different reasons and concerns about participating in 
clinical research.17 A scientific examination of this issue may 
generate critical feedback that could improve the execution 
of clinical trials.
We conducted a cross-sectional, controlled, multicenter 
survey in various academic and nonacademic pharmaceutical 
clinical research sites. The primary end point was to assess 
participant’s perception (ie, regard and understanding) of 
clinical research trials in a large population with one of four 
highly prevalent chronic diseases: type 2 diabetes, hyperten-
sion, chronic obstructive pulmonary disease, and rheumatoid 
arthritis. The secondary end point was to compare their 
perceptions by sex, age, and disease to determine whether 
they were influenced by the inherent characteristics of the 
participant categories classified by these variables.
Methods
study participants
Ethics approval was obtained from Comité de Ética en 
Investigación de la Facultad de Medicina y Hospital Univer-
sitario de la Universidad Autónoma de Nuevo León. From 
September 2013 to March 2014, research sites consecutively 
enrolled patients who met all eligibility criteria. Cases were 
males and females, aged 18–80 years, who had lived in 
Mexico for at least 10 years, who had participated or were 
currently participating in Phase II or III pharmaceutical 
industry-funded clinical trials, and who had attended at least 
their sixth visit. Trial participants (cases) were recruited in 
equally proportionate populations among each of the four 
chronic degenerative disorders evaluated (type 2 diabetes, 
hypertension, chronic obstructive pulmonary disease, and 
rheumatoid arthritis). In the eventuality of studied comorbidi-
ties, the disease of interest in their clinical trial determined the 
assignment into our study disease groups. These four chronic 
diseases were chosen because of their high prevalence and 
the high number of approved treatments already available and 
because they have a low short-term risk of death or serious 
complications. Cases were paired (correspondingly distrib-
uted by disease) with controls, who had never participated 
in, or been invited to participate in, a clinical trial and who 
had visited the primary care and specialty outpatient clinics 
for reasons other than trials. Recruitment took place in 12 
clinical research sites throughout Mexico. All participants 
provided written informed consent and were able to complete 
the self-survey.
clinical research sites
All the research sites had participated in pharmaceutical 
research (in .45 clinical trials), for at least 10 years, and 
had a professional pharmaceutical research team; nine out of 
the 12 sites had sections within their facilities designated for 
conducting clinical trials. All sites also provided primary care 
and specialty outpatient services to the general population.
study protocol
Cases were invited to participate while attending their research 
study site and controls while at their specialty outpatient 
clinics. In all cases, a staff member, unrelated to the trial the 
patient was enrolled in, acquired the patient’s demographic 
data and explained the survey. Any questions from partici-
pants were clarified by the research site staff in charge of the 
surveys. Once finished, the evaluator reviewed whether the 
survey was correctly completed. After completion, all surveys 
were sent back to a central site for data management.
Procedures
The survey was developed by two of the authors (JGGG and 
JLVM) with .15 years of experience in original and pharma-
ceutical clinical research, based on their experience in day-to-
day clinical research activities. A two-phase prepilot study and 
a pilot study were performed to validate the survey. First, the 
original draft was tested in two focus groups, each with seven 
to eight participants (80% previously involved in a clinical 
research study). Then, two individual semistructured interviews 
were randomly chosen to be used in six out of the 12 sites (12 
interviews in total). Key points mentioned by the participants 
in each stage were used to revise the questions and their order 
of appearance in the survey. After this, a final questionnaire 
was formulated and piloted in a total of 30 individuals who had 
the same eligibility criteria as the ones included in this study. 
Minor inconsistencies were found and taken into account to 
draft the survey used in this study (Supplementary material). 
All surveys were completed with paper and pencil.
One hundred surveys were sent to each research site: 50 
for cases and 50 for controls. In all research sites, the staff 
member responsible for survey application received a careful 
explanation about the procedure and possible questions that 
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could arise during the evaluation. We analyzed 17 multiple-
choice questions: each with two to eight choices. Both 
cases and controls were surveyed with the same questions 
in addition to a unique question specifically designed for 
each group. Data presented in this article are a fraction of 
the whole survey, given that it assessed diverse subtopics 
regarding participants’ perception of clinical research. This 
study focused on the general perception and motives for 
participation in pharmaceutical clinical research.
statistical analysis
All results are reported as mean ± SD unless otherwise stated. 
A P-value #0.05 was statistically significant. Descriptive 
statistics were used for quantitative variables, measures of 
central tendency, and dispersion. In the case of qualitative 
variables, frequencies were obtained. In quantitative compar-
ative data, we used an unpaired Student’s t-test. The response 
differences between groups were studied using Pearson’s 
χ2 test or Fisher’s exact test for 2×2 tables. The statistical 
analysis was performed using IBM SPSS Statistics 20.0 (IBM 
Corporation, Armonk, NY, USA).
Results
study population
Demographic and clinical characteristics of the study popu-
lation are shown in Table 1. A total of 1,208 participants 
were included: 604 cases and an equal number of controls. 
All participants approached agreed to be included. Two-
thirds of the cases (65.4%) were participating in pharma-
ceutical research for the first time. Cases were significantly 
older than controls (54.8±13.9 years vs 47.0±15.5 years, 
P,0.05). Two-thirds of cases and controls were female. 
More than one-third of the whole study population had at 
least 9 years of education, and .75% had access to social 
or private health insurance.
Perception of pharmaceutical clinical 
research
The most and least common responses are shown in Table 2. 
Unless otherwise stated, statistical analysis by sex, age, and 
disease category was not different from the results found in 
the statistics as a whole group.
To cure more diseases and to do so more effectively were 
considered the main reasons for pharmaceutical companies to 
conduct clinical trials (cases 65.4%; controls 50.7%). More 
cases (98.8%) than controls (81.3%) believed that it is correct 
to perform research on humans. Controls considered trials as 
a business (4.3%), more so than cases (0.5%), and were more 
likely to believe that its risks outweigh the benefits (controls 
12.1% vs cases 1.2%).
More cases felt protected in case of a serious adverse 
event related to the experimental drugs (93.4%) compared 
Table 1 Demographic and clinical characteristics of the study population
Characteristic Study population DM2 COPD RA HT
Cases 
(n=604)
Controls 
(n=604)
Cases 
(n=151)
Controls 
(n=151)
Cases 
(n=151)
Controls 
(n=151)
Cases 
(n=151)
Controls 
(n=151)
Cases 
(n=151)
Controls 
(n=151)
Age, mean ± sD (years) 54.9±13.9 47.1±15.5* 52.2±12.8 46.6±15.7* 60.3±14.2 53.1±16.7* 50.1±13.4 41.6±15.3* 56.8±13.1 47±12.1*
Age group, n (%)
,50 years 216 (35.8) 320 (53.0)* 68 (45.0) 83 (55.0) 31 (20.5) 57 (37.7)* 71 (47.0) 103 (68.2)* 46 (30.5) 77 (51.0)*
$50 years 388 (64.2) 284 (47.0) 83 (55.0) 68 (45.0) 120 (79.5) 94 (62.3) 80 (53.0) 48 (31.8) 105 (69.5) 74 (49.0)
sex, n (%)
Female 377 (62.4) 394 (65.2) 101 (66.9) 95 (62.9) 69 (45.7) 92 (60.9)** 126 (83.4) 110 (72.8)** 81 (53.6) 97 (64.2)
Male 227 (37.6) 210 (34.8) 50 (33.1) 56 (37.1) 82 (54.3) 59 (39.1) 25 (16.6) 41 (27.2) 70 (46.4) 54 (35.8)
Years of education, n (%)
,9 years 363 (60.1) 341 (56.5) 90 (59.6) 82 (54.3) 89 (58.9) 76 (50.3) 90 (59.6) 85 (56.3) 94 (62.3) 98 (64.9)
$9 years 241 (39.9) 263 (43.5) 61 (40.4) 69 (45.7) 62 (41.1) 75 (49.7) 61 (40.4) 66 (43.7) 57 (37.7) 53 (35.1)
health care, n (%)
Yes 476 (78.8) 453 (75) 122 (80.8) 118 (78.1) 116 (76.8) 121 (80.1) 112 (74.2) 116 (76.8) 126 (83.4) 98 (64.9)*
no 128 (21.2) 151 (25) 29 (19.2) 33 (21.9) 35 (23.2) 30 (19.9) 39 (25.8) 35 (23.2) 25 (16.6) 53 (35.1)
Previous clinical trial participation (case group only), n (%)
One 395 (65.4) 89 (58.9) 89 (58.9) 119 (78.8) 98 (64.9)  
Two to three 196 (32.5) 60 (39.7) 56 (37.1) 28 (18.5) 52 (34.4)  
Three to six 10 (1.7) 2 (1.3) 5 (3.3) 2 (1.3) 1 (0.7)  
More than six 3 (0.5)  0 (0)  1 (0.7)  2 (1.3)  0 (0)  
Notes: *P#0.001; **P#0.05.
Abbreviations: cOPD, chronic obstructive pulmonary disease; DM2, diabetes mellitus type 2; hT, hypertension; rA, rheumatoid arthritis.
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Table 2 comparison of the two most and least common answers between cases and controls
Questions and answers Case group 
(n=604)
Control group 
(n=604)
P-value
 1. Why do pharmaceutical companies do research?
To cure more diseases and do so more effectivelya 395 (65.4) 306 (50.7) #0.001
To find out whether new medications will be more effective and securea 131 (21.7) 145 (24)
Because research of new drugs is a businessb 3 (0.5) 26 (4.3)
so physicians can have new medicationsb 14 (2.3) 12 (2)
 2. Do you believe it is correct to perform research studies on humans?
Yes 597 (98.8) 491 (81.3) #0.001
no 7 (1.2) 113 (18.7)
 3. Why do you believe that performing research on humans is reasonable? n=597 n=491
it is a good and reasonable option for people who cannot afford treatment by themselvesa 247 (41.4) 162 (33) #0.001
it is reasonable as long as patients are closely monitored to identify the risks that could arisea 167 (28) 153 (31.2)
it is reasonable only in the case of certain diseases such as cancerb 2 (0.3) 5 (1)
 4. Why do you believe that performing research on humans is “not” reasonable? n=7 n=113
Because human beings must not be treated like “guinea pigs”a 5 (71.4) 55 (48.7) 0.727
Because research is only conducted on people without other health care alternativesa 0 (0) 13 (11.5)
Because in our country, medical researchers and the sites, where research is conducted, are not 
under surveillanceb
0 (0) 13 (11.5)
Because health is put at riskb 0 (0) 6 (5.3)
 5. What benefits do you believe Mexico, as a country, may obtain by participating in research studies conducted by pharmaceutical companies?
To promote the development of clinical research centers and research physiciansa 360 (59.6) 370 (61.3) 0.011
To offer expensive high-quality medical health care but free of charge to participantsa 90 (14.9) 73 (12.1)
To offer the participants medications not yet available to the general publicb 73 (12.1) 73 (12.1)
I do not believe there are any benefitsb 5 (0.8) 20 (3.3)
 6. What benefits do you believe a patient may obtain by participating in a research study conducted by a pharmaceutical company?
Participants receive free medical extra services besides the experimental drug such as education 
about their disease, nutritional evaluation and guidelines, medical equipment (eg, glucometer), etca
391 (64.7) 343 (56.8) #0.001
Participants receive excellent medical carea 129 (21.4) 68 (11.3)
In most cases, the benefits are minimal; instead, participants expose themselves to risksb 7 (1.2) 34 (5.6)
I do not believe there are any benefitsb 0 (0) 30 (5)
 7. in case of a serious adverse event related to the experimental drug that could lead to a complication or disability, do you believe that a study 
participant is protected?
Yes 564 (93.4) 416 (68.9) #0.001
no 40 (6.6) 188 (31.1)
 8. Why do you consider the participant is protected? n=564 n=416
research physicians take care of defending and protecting the participanta 414 (73.4) 282 (67.8) 0.037
i am aware that the company takes responsibility for and takes care of everythinga 101 (17.9) 76 (18.3)
The ethics committee will defend the participant’s position; the pharmaceutical company will 
have to comply with what they determineb
45 (8) 49 (11.8)
 9. Why do you consider the participant is “not” protected? n=40 n=188
Because in case a problem arises, no one will defend the patient properlya 16 (40) 74 (39.4) 0.167
Because the company can argue that the problem was not caused by the experimental druga 15 (37.5) 87 (46.3%)
Because medical researchers side with the company’s interests and not the patient’sb 3 (7.5) 17 (9)
10. Do you believe that in research projects the participant’s health is put at risk?
Yes 201 (33.3) 344 (57) #0.001
no 403 (66.7) 260 (43)
11. Which do you believe is the reason people do risk participating? n=201 n=344
Because the health risks are minimal and if there was any problem, the physician would detect it 
on timea
69 (34.3) 83 (24.1) #0.001
Even though there are risks, the new medications offer more benefits than those offered to the 
general publica
58 (28.9) 73 (21.2)
Because even though health risks are high, sometimes there is no other option to get clinical careb 9 (4.5) 56 (16.3)
i am not aware that our health is put through any important risksb 8 (4) 5 (1.5)
12. Why do you believe there are no health risks in these studies? n=403 n=260
i believe it is important that participants are under major monitoring by the physiciana 213 (52.9) 131 (50.4) #0.001
I know there is a committee that makes sure that participants get more benefits than risks for 
their health. i trust thema
54 (13.4) 29 (11.2)
(Continued)
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Table 2 (Continued)
Questions and answers Case group 
(n=604)
Control group 
(n=604)
P-value
Because i am sure that the physician would not invite me to participate if there were any risksb 18 (4.5) 44 (16.9)
i simply do not believe there are risks involvedb 12 (3) 6 (2.3)
13. Do you believe that the most important reason that motivates a person to participate in this type of studies is the fact that everything is free, 
including medications?
Yes 314 (52) 329 (54.5) #0.001
no 248 (41.1) 177 (29.3)
i do not know 42 (7) 98 (16.2)
14. Would you recommend others to participate in a pharmaceutical clinical trial?
Yes 599 (99.2) 468 (77.5) #0.001
no 5 (0.8) 136 (22.5)
15. Would you recommend a person without financial limitations to get clinical care to participate in a pharmaceutical clinical trial?
Yes 497 (82.3) 361 (59.8) #0.001
no 107 (17.7) 243 (40.2)
16. Would you participate in a drug research study of the pharmaceutical industry? (control group only)
Yes – 367 (60.8)
no – 237 (39.2)
17. Would you participate in another drug research study of the pharmaceutical industry? (case group only)
Yes 549 (90.9) –
no 7 (1.2) –
i do not know 48 (7.9) –  
Notes: Data were given as n (%). aMost common answer. bleast common answer.
to controls (68.9%). Correspondingly, less cases (33.3%) 
than controls (57%) considered their health was at risk if 
participating in pharmaceutical clinical trials.
For both groups, the fact that everything is free in clinical 
trials ranked as the most important motivation to enroll (cases 
52%; controls 54.5%). Yet, cases (82.3%) would recommend 
participating in trials disregarding financial capability to 
afford medical care more so than controls (59.8%). Finally, 
90.9% of cases expressed that they would participate in a drug 
research study again, while only 60.8% of controls would 
consider participating in a clinical trial.
Discussion
Participants’ perception about clinical trials can be quite 
different depending on the severity, prognosis, and available 
treatment options of their disease. Most studies evaluating 
perceptions in clinical trials have been carried out in partici-
pants with cancer, HIV, and hepatitis C.17–24 These patients, 
frequently nonresponders to standard-of-care medications, are 
more likely to consider research treatments as an unavoidable 
alternative, making their perceptions biased and therefore 
unfit to be generalized to many other diseases. In addition, 
studies that have included a broad variety of disorders have 
not analyzed if the participants’ diseases have affected their 
results.10,11,13,16 We studied an adult population with one 
of four common chronic diseases. These diseases all have 
many available and approved therapeutic choices and a low 
life-threatening risk in the short-to-medium term. Also, most 
participants had access to private or social health insurance. 
Because of this, our findings represent a more accurate evalu-
ation of the reasons and perceptions to participate in clinical 
trials funded by the pharmaceutical industry.
This multicenter study is the first to be conducted in 
Mexico exploring the perceptions of volunteer participants 
of industry-funded clinical trials. Its design allowed us to 
find that the degree of knowledge that participants have 
about the process of pharmaceutical clinical research directly 
influences their final perception, in contrast with the percep-
tions of nonparticipants with the same disease. Significantly, 
almost all cases (98.8%) considered that conducting research 
studies in humans is “correct” in contrast to just four out 
of five controls. Nearly one-tenth of controls mentioned 
the concept of “guinea pigs” when referring to research 
participants. The majority of cases and controls agreed that 
the ultimate purposes of clinical research are positive with 
the main concept being “to cure more diseases and to do so 
more effectively” and “to find out whether new medications 
will be more effective and secure”. Nevertheless, nearly nine 
times more controls than cases still believed that the main 
purpose of clinical research is business or that it is carried 
out just to “face competition with other companies”.
To better understand the meaning of these results, we need 
to consider that the general public image of the pharmaceutical 
industry is weak or highly negative almost everywhere.25,26 
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There is public concern about the apparent judgment of 
medications as “nothing more than a consumerist tool”, and 
this idea is naturally extended to the clinical research funded 
by the pharmaceutical industry.27,28 Patients’ perception 
improves if individuals have participated in a clinical trial, 
as also observed by the Center for Information and Study 
on Clinical Research Participation.16 Significantly, in our 
report, nearly 95% of the cases clearly identified the benefits 
of their participation in the trial. In contrast, ten times more 
controls than cases believed that clinical trials granted none or 
minimal benefits to participants. Supporting these results, we 
found that 90.9% of cases would participate in another study, 
given the opportunity. Kost et al also found that 97% of the 
population surveyed would recommend research participation 
to family or friends.13 In our study, almost all cases (99.2%) 
would invite another person to participate in a clinical trial, 
in contrast to 77.5% of the controls. Furthermore, .80% of 
the cases would recommend participating in a clinical trial 
to anyone, irrespective of whether they could afford to pay 
for the treatment themselves, compared to only 59.8% in 
the control group, which is a significant difference. These 
findings reveal that participants perceive that pharmaceutical 
research offers a high-value medical treatment, regardless of 
the economic status of the individual.
Meropol et al reported that although oncology patients and 
physicians are aware of the trials’ benefits, three psychosocial 
barriers impact participation such as: random assignment, fear 
of receiving placebo, and fear of side effects.29 In our study, 
significantly more cases (93.4%) than controls (68.9%) felt 
protected in case of an adverse event, mainly because they 
trusted the investigator and because they were “aware that 
the company takes responsibility and takes care of every-
thing”. Almost one-third of the controls, however, had the 
perception that study participants are not protected and half 
of them believed that “in case a problem arises, no one will 
defend the patient properly”. In addition, significantly more 
controls (57%) than cases (33.3%) considered that in research 
projects the participant’s health is endangered; however, cases 
believed that the patients’ main reason to participate anyway 
is “because the health risks are minimal and if there was any 
problem, the physician would detect it on time”.
Participants who considered that their health was not at 
risk when entering a clinical trial (cases 66.7% vs controls 
43%) did so because they believed that the patients are 
under close and permanent physician surveillance (cases 
52.9% vs controls 50.4%) and because “I know there is a 
committee that makes sure that participants get more benefits 
than risks for their health. I trust them”. Campbell et al30 
reported how the negative reputation of research in human 
participants may impact study enrollment. This negative 
factor conveys the lack of understanding from the public 
about the methods and purposes of clinical research and the 
regulatory and ethical safeguards that the research process 
has nowadays to protect participants. The work invested on 
protecting the participants, frequently performed by profes-
sional researchers, by certified ethical committees, and by 
academic institutions, is generally unknown to the public; 
these evidences, in contrast to pharmaceutical industry-
related negative events, are scarcely publicized.3 Therefore, 
it is necessary to provide potential research participants with 
adequate information.31 Furthermore, regulatory agencies in 
all countries must approve and certify that clinical research 
is carried out in professional research sites with committed 
and certified ethical committees, in order to guarantee that 
all issues that may arise during the execution of a clinical 
trial are properly handled. It is worthy to mention that the 
results of this study are in accordance with other reports 
from academic institutions also staffed with professional 
researchers.10–13 It would prove useful to test our survey on 
research sites with inadequately trained personnel participat-
ing as collaborators of clinical trials, participants with other 
diseases, and multinational collaborative studies.
Similarly to our findings, Llewellyn-Thomas et al 
showed that patients who choose to enter a clinical trial 
differ substantially from those who choose not to.32 As 
described earlier, almost in every item, we found significant 
differences between the perception of cases and controls. 
However, both groups of our study coincide in the notion 
that the most important motivation to participate in a study is 
because everything is free of charge. In Mexico, as a devel-
oping country, the cost of medical care should be considered 
as an important factor in the final decision to participate in 
a pharmaceutical trial. Despite the fact that .75% of the 
participants had access to social or private health insurance, 
they decided to participate in a clinical trial. As reasonably 
expected, our findings differ from those found in developed 
countries where “to help others” (64%) and “concern about 
the topic” (56%) were considered “very important” reasons 
to participate in a research study, and answers such as “to 
earn money” and “to obtain free health care” were less 
frequent.13 As recently reported by Ipsos Global Reputation 
Centre, negative perception about the pharmaceutical indus-
try is worse in industrialized countries than it is in emerging 
markets, and interestingly Mexico is one of the countries 
where the industry is viewed less unfavorably.33 We further 
support this concept because 96%–99% of the participants 
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in our study recognized the benefits that Mexico has by 
participating in pharmaceutical industry research. This infor-
mation could help us have a better perspective of our results, 
when compared to experiences documented elsewhere. As 
Nathan recommended, our study shows how important it 
is to promote the recognized benefits of industry-funded 
biomedical research among the general public, considering 
that the lack of knowledge is producing a potential loss of 
confidence in this activity and is currently threatening the 
final purpose of clinical research.34
Conclusion
Our multicenter study, in a developing country, in a large 
population of participants and nonparticipants of pharma-
ceutical clinical trials, most with access to health insurance 
and with one of four chronic and highly prevalent disorders 
with many available and approved treatments, could indicate 
that clinical trial participation has a positive influence on 
the perception of pharmaceutical industry-funded clinical 
research. Participants become aware of the benefits they 
obtain by enrolling in clinical trials and the rewards of con-
ducting them for the whole country. They also may acquire 
a sense of security by perceiving that the site staff is capable 
of handling adverse events, view their current and future 
participation in clinical trials as a benefit to their health rather 
than a risk, and would recommend enrollment to others, 
regardless of their financial status. However, “free of charge 
medical attention” and “an option for people without health 
insurance” are strongly prevalent reasons for participation. 
All this information needs to be conveyed to clinicians, public 
health authorities, and the general population to overcome 
misconceptions. Still more information is needed regarding 
the evaluation of participants’ perception in other issues that 
must be included in high-quality clinical research besides the 
measurement of the good clinical practice standards during 
clinical trial execution. Issues such as participant satisfaction, 
beneficence, value of participation, empathy, and participant 
information regarding their participation in the trial still need 
to be thoroughly analyzed.
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